Live
- Top 5 Supercars to Rent in Dubai for Adrenaline Seekers
- Nagesh Trophy: Telangana, Gujarat dominate action on Day 4 with easy wins
- Get Ready for Dreame Technology’s Year-End Amazon Sale – Big Savings on Smart Home Products
- FIR registered as 4 voter forgery cases come to light in Delhi's Okhla constituency
- Ayodhya Ram temple to host majestic anniversary celebrations on Jan 11 with devotional, cultural programmes
- National Policy Framework on Agricultural Marketing draft silent on MSP: Punjab
- Thyrocare Sets Benchmark as The First National Diagnostic Chain with 100% of its Labs with NABL Accreditation
- Hisense India Partners with Reliance resQto Elevate After-Sales Service Nationwide
- RG Kar tragedy: CFSL reports suggest further probe to find whether rape & murder committed by only one or others involved
- PM Modi takes stock of 8 big infra projects worth Rs 1 lakh crore
India’s Natco Pharma sued in US
The Hyderabad based pharmaceutical major Natco Pharma Ltd on Friday said the company and others have been named as defendants in a case filed in the US.
Chennai: The Hyderabad based pharmaceutical major Natco Pharma Ltd on Friday said the company and others have been named as defendants in a case filed in the US.
In a regulatory filing Natco Pharma said, the company along with Celgene Corporation, Bristol Myers Squibb and Breckenridge Pharmaceutical Inc., have been named as defendants in an antitrust lawsuit in the US.
The suit was filed by Louisiana Health Service & Indemnity Company D/B/A Blue Cross and Blue Shield of Losisiana and HMO Louisiana Inc., regarding Pomalidomide (Pomalyst). Pomalidomide is a generic drug for cancer.
"Natco believes this matter is without merit. Breckenridge is the ANDA (abbreviated new drug application) holder and distribution partner for the generic product in the US," Natco said.
Meanwhile Natco Pharma's scrip that opened at Rs.917.75 on Friday went down and was changing hands at about Rs 882.
